Novo Nordisk has reported 10 deaths and over 100 hospitalizations linked to compounded versions of its weight-loss drug semaglutide, known as Ozempic and Wegovy. The Medicines and Healthcare products Regulatory Agency (MHRA) has also documented 10 deaths and 7,228 side effects associated with GLP-1 receptor agonists, prompting healthcare professionals to monitor for misuse and counterfeit medications. The FDA issued a warning regarding the risk of pulmonary aspiration for patients taking these drugs before surgery, as they can slow gastric emptying. Novo Nordisk's CEO emphasized that only their manufactured semaglutide is safe and warned against the risks of unregulated compounded versions. The company has requested the FDA to ban compounding pharmacies from creating these copycat drugs, highlighting safety concerns. Both Novo Nordisk and regulatory agencies are addressing the implications of these findings as patient safety remains a priority.